title: Intravenous immunoglobulin G (IVIG) inhibits IL-1- and TNF-α-dependent, but not chemotactic-factor-stimulated, neutrophil transendothelial migration.
abstract: High-dose intravenous immunoglobulin (IVIG) has anti-inflammatory effects via incompletely understood mechanisms. By investigating whether IVIG might modulate neutrophil (PMN) recruitment, we observed that IVIG dose-dependently inhibited (by 30-50%) PMN transendothelial migration (TEM) across human umbilical vein endothelial cells (EC) stimulated with IL-1α, IL-1β, TNF-α or IL-1β+TNF-α. Inhibition required the presence of IVIG with the responding PMNs, was attributable to the F(ab)(2) portion and was unrelated to putative contaminants in IVIG. IVIG did not inhibit IL-1β- or TNF-α-induced increase of PMN adhesion to EC, nor did it affect C5a- or IL-8-induced PMN TEM across unstimulated EC. Effects of IVIG and F(ab)(2) fragments were not associated with PMN activation, assessed by CD62L shedding, CD11b upregulation or PMN shape. Thus, IVIG selectively inhibits PMN TEM across inflammatory-cytokine-stimulated - but not unstimulated - EC, perhaps contributing to therapeutic benefit in chronic inflammation with minimal impact on chemotactic-factor-induced PMN recruitment during acute infection.
authors.affiliation: Department of Pediatrics, Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada. andrew.issekutz@iwk.nshealth.ca
authors.forename: Andrew C
authors.initials: AC
authors.lastname: Issekutz
authors.forename: Derek
authors.initials: D
authors.lastname: Rowter
authors.forename: Heather F
authors.initials: HF
authors.lastname: Macmillan
mesh_terms: D039481:CD11b Antigen / Q000096:biosynthesis; D002448:Cell Adhesion / Q000187:drug effects; D002478:Cells, Cultured / Q000166:cytology / Q000187:drug effects; D002630:Chemotactic Factors / Q000494:pharmacology*; D015936:Complement C5a / Q000276:immunology; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology*; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology*; D066298:In Vitro Techniques; D007239:Infections / Q000276:immunology; D007249:Inflammation / Q000276:immunology; D053582:Interleukin-1alpha / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D016209:Interleukin-8 / Q000276:immunology; D019041:L-Selectin / Q000096:biosynthesis; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects*; D057705:Transendothelial and Transepithelial Migration / Q000187:drug effects*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology; D014471:Umbilical Veins
chemical_list: D039481:CD11b Antigen; D002630:Chemotactic Factors; C509295:ITGAM protein, human; D007140:Immunoglobulin Fab Fragments; D016756:Immunoglobulins, Intravenous; D053582:Interleukin-1alpha; D053583:Interleukin-1beta; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D019041:L-Selectin; D015936:Complement C5a